Systematic review of oncological outcomes following laparoscopic vs open total mesorectal excision

Muhammad Shafique Sajid, Adil Ahamd, William FA Miles, Mirza Khurrum Baig

Muhammad Shafique Sajid, Adil Ahamd, William FA Miles, Mirza Khurrum Baig, Department of General, Endoscopic and Laparoscopic Colorectal Surgery, Western Sussex Hospitals NHS Trust, Worthing Hospital, Worthing, West Sussex, BN11 2DH United Kingdom

Author contributions: All authors contributed substantially in literature search, data extraction, trial selection, statistical analysis, and final drafting of this article; Sajid MS contributed to idea conception, data analysis, data interpretation, draft writing; Ahmad A contributed to draft writing; Miles WFA contributed to data confirmation, data interpretation, draft writing and supervising the study.

Correspondence to: Muhammad Shafique Sajid, Surgical Specialist Registrar, Department of General, Endoscopic and Laparoscopic Colorectal Surgery, Western Sussex Hospitals NHS Trust, Worthing Hospital, Washington Suite, North Wing, West Sussex, BN11 2DH, United Kingdom. surgeon1wrh@hotmail.com

Telephone: +44-1903-205111 Fax: +44-1903-285010

Received: November 29, 2013 Revised: February 27, 2014

Accepted: March 11, 2014

Published online: May 16, 2014

Abstract

AIM: To systematically analyze the randomized trials comparing the oncological and clinical effectiveness of laparoscopic total mesorectal excision (LTME) vs open total mesorectal excision (OTME) in the management of rectal cancer.

METHODS: Published randomized, controlled trials comparing the oncological and clinical effectiveness of LTME vs OTME in the management of rectal cancer were retrieved from the standard electronic medical databases. The data of included randomized, controlled trials was extracted and then analyzed according to the principles of meta-analysis using RevMan® statistical software. The combined outcome of the binary variables was expressed as odds ratio (OR) and the combined outcome of the continuous variables was presented in the form of standardized mean difference (SMD).

RESULTS: Data from eleven randomized, controlled trials on 2143 patients were retrieved from the electronic databases. There was a trend towards the higher risk of surgical site infection (OR = 0.66; 95%CI: 0.44-1.00; z = 1.94; P < 0.05), higher risk of incomplete total mesorectal resection (OR = 0.62; 95%CI: 0.43-0.91; z = 2.49; P < 0.01) and prolonged length of hospital stay (SMD, -1.59; 95%CI: -0.86--0.25; z = 4.22; P < 0.00001) following OTME. However, the oncological outcomes like number of harvested lymph nodes, tumour recurrence and risk of positive resection margins were statistically similar in both groups. In addition, the clinical outcomes such as operative complications, anastomotic leak and all-cause mortality were comparable between both approaches of mesorectal excision.

CONCLUSION: LTME appears to have clinically and oncologically measurable advantages over OTME in patients with primary rectal cancer in both short term and long term follow ups.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

Key words: Total mesorectal excision; Anterior resection; Abdominoperineal resection; Rectal cancer; Oncological outcomes

Core tip: Based upon the findings of this systematic review of eleven randomized trial on 2143 patients of rectal cancer, there is a higher risk of surgical site infection, higher risk of incomplete total mesorectal resection and prolonged length of hospital stay following open total mesorectal excision (OTME) compared to laparoscopic total mesorectal excision (LTME). The number of harvested lymph nodes, tumour recurrence and risk of positive resection margins were statistically similar in both groups. In addition, the operative complications, anastomotic leak and mortality were compa-
rable between LTME and OTME. LTME appears to have clinically and oncologically measurable advantages over OTME in patients with primary resectable rectal cancer.

INTRODUCTION

Colorectal cancer is one of the major causes of mortality among western population\(^{[1,2]}\). Radical resection of the rectum in the form of anterior resection and abdominoperineal resection has been advocated for many decades to achieve highest level of oncological clearance and overall survival\(^{[3,8]}\). The introduction of total mesorectal excision in the management of rectal cancer has also enhanced survival and reduced the risk of local recurrence\(^{[9-14]}\) because it achieves complete excision of the rectum together with its lymphatics and lymph nodes. Therefore, total mesorectal excision has become gold standard surgical strategy to treat rectal malignancies\(^{[10,11]}\). Laparoscopic total mesorectal excision (LTME) offers several advantages over conventional and orthodox open total mesorectal excision (OTME) such as reduced blood loss, faster recovery, reduced postoperative pain score, early feeding, early return to normal activities and a reduced risk of postoperative complications\(^{[20,21]}\). However, these advantages of LTME can only be availed optimally by colorectal surgeons when its oncological viability is proven on scientific grounds. One would assume that LTME for rectal cancer should offer survival and recurrence similar to OTME\(^{[17,19]}\). In addition, several studies have also reported the concerns towards LTME requiring longer duration of operation, needing extensive learning curve for colorectal surgeons, particularly junior colorectal trainees and cost implications of the procedure\(^{[20,21]}\). Aforementioned three limitations of LTME can be offset if its oncological and clinical adequacy matches the OTME. The objective of this article is to explore the oncological safety and clinical effectiveness of the LTME comparing to OTME based upon the principles of meta-analysis.

MATERIALS AND METHODS

Electronic data sources and their search planning

In order to obtain pertinent studies, a search of common medical electronic databases such as MEDLINE, EMBASE, and the Cochrane library for randomized, controlled trials was conducted and screened according to PRISMA flow chart (Figure 1). The MeSH terms published in the Medline library relevant to the oncological and clinical outcomes following LTME or OTME were used to hit upon the relevant studies. No limits for language, gender, sample size and place of study origin were entered for the search in the database search engine. Boolean operators (AND, OR, NOT) were additionally used to narrow and widen the results of potentially usable studies. The titles of the published articles from the search results were examined closely and determined to be suitable for potential inclusion into this review article. The reference list from selected articles was also examined as a further search tool to discover additional trials.

Selection criteria for included trials

For inclusion in this meta-analysis, a study had to fulfill the following criteria: (1) randomized, controlled trial; (2) comparison between LTME and OTME; (3) evaluation of a well-defined primary outcome; (4) main outcome measures reported preferably as an intention-to-treat (ITT) analysis; and (5) trials on surgical patients those have endoscopically and histologically proven rectal cancer.

Data abstraction from included trials

Two independent reviewers using a predefined meta-analysis form abstracted relevant data of oncological and clinical outcomes following LTME and OTME from each study which resulted in high and satisfactory interobserver agreement. The extracted data contained name of the publishing authors, title of the published study, journal in which the study was published, country and year of the study, intervention protocol in the both limbs of the trial, method by which LTME and OTME was performed, testing sample size (with sex differentiation if applicable), the number of patients receiving each regimen and within the group the number of patients who succeeded and the number of patients who failed the allocated treatment, the patient compliance rate in each group, the number of patients reporting complications and the number of patients with absence of complications in each arm of the trial. After completing the data abstraction the two independent reviewers discussed the data related results and, if discrepancies were present, a consensus was reached.

Statistical analysis

The software package RevMan 5.2\(^{[22,23]}\), provided by the Cochrane Collaboration, was used for the statistical analysis. The odds ratio (OR) with a 95% CI was calculated for binary data, and the standardized mean difference (SMD) with a 95% CI was calculated for continuous variables. The random-effects model\(^{[24,25]}\) was used to calculate the combined outcomes of both binary and continuous variables. Heterogeneity was explored using the \(\chi^2\) test, with significance set at \(P < 0.05\), and was quantified\(^{[26]}\) using \(I^2\) with a maximum value of 30 percent identifying low heterogeneity\(^{[28]}\). The Mantel-Haenszel method was used for the calculation of OR under the random effect models\(^{[27]}\). In a sensitivity analysis, 0.5 was added to each cell frequency for trials in which no event occurred in either
the treatment or control group, according to the method recommended by Deeks et al. If the standard deviation was not available, then it was calculated according to the guidelines of the Cochrane Collaboration. This process involved assumptions that both groups had the same variance, which may not have been true, and variance was either estimated from the range or from the P-value. The estimate of the difference between both techniques was pooled, depending upon the effect weights in results determined by each trial estimate variance. A forest plot was used for the graphical display of the results. The square around the estimate stood for the accuracy of the estimation (sample size), and the horizontal line represented the 95%CI. The methodological quality of the randomized, controlled trials was assessed using the published guidelines of Jaddad et al. and Chalmers et al. The quality of majority of included randomized, controlled trials was considered good. Only three included trials were scored of low quality due to the absence of adequate randomisation technique, power calculations, blinding, adequate concealment process and lack of intention-to-treat analysis. Based on the quality of included trials, the strength and summary of the evidence analyzed on GradePro, a tool provided by the Cochrane Collaboration.

Outcomes

Incidences of complete TME was analysed as primary endpoint in this study. Secondary endpoints included circumferential resection margin (CRM) positivity, number of harvested lymph nodes, mortality, morbidity, anastomotic leak, surgical site infection and length of hospital stay.

RESULTS

Eleven randomized, controlled trials encompassing 2143 patients were retrieved from the electronic databases. There were 1189 patients in the LTME group and 954 patients in the OTME group. The characteristics of the included trials are given in Table 1. The salient features and treatment protocols adopted in the included trials are given in Table 2. We used the data from one publication only from two published articles of same randomized, controlled trial in order to avoid the duplication of data.

Methodological quality of included studies

Based upon the published guidelines of Jaddad et al. and Chalmers et al. the quality of majority of included randomized, controlled trials was considered good. Only three included trials were scored of low quality due to the absence of adequate randomisation technique, power calculations, blinding, adequate concealment process and lack of intention-to-treat analysis. Based on the quality of included trials, the strength and summary of the evidence analyzed on GradePro is given in Figure 2. The reported quality variables of included trials are given in Table 3.

Risk of incomplete total mesorectal excision

There was no heterogeneity among included studies. In the random effects model (OR = 0.62; 95%CI: 0.43-0.91; I² = 24.9; P < 0.01; Figure 3A), the risk of incomplete total mesorectal excision was higher following OTME compared to LTME.

Risk of positive circumferential resection margins

There was no heterogeneity among included studies. In the random effects model (OR = 0.98; 95%CI: 0.63, 1.51; I² = 0.10; P = 0.71; Figure 3B), the risk of positive circum-
Table 1 Characteristics of included trials

| Ref.              | Year | Country | Age (yr) | Gender (M:F) | Follow up (mo) | Rectal cancer details                                                                 | Procedure                      |
|-------------------|------|---------|----------|--------------|----------------|----------------------------------------------------------------------------------------|--------------------------------|
| Araujo et al[25]  | 2003 | Brazil  | 59.1     | 9:4          | 47.2           | Lower rectal cancer with neoadjuvant chemoradiotherapy                                  | Abdominoperineal resection    |
| OTME              |      |         | 56.4     | 10:5         |                |                                                                                        |                                |
| Baraga et al[22]  | 2007 | Italy   | 62.8 ± 12.6 | 55:28        | 53.6           | Adenocarcinoma of the rectum                                                          | Anterior resection and        |
| OTME              |      |         | 65.3 ± 10.3 | 64:21        |                |                                                                                        | Abdominoperineal resection    |
| Gong et al[26]    | 2012 | China   | 58.4 ± 13.6 | 1:3:1         | 21 (9-56)      | Lower and mid rectal adenocarcinoma without neoadjuvant chemoradiotherapy              | Anterior resection and        |
| OTME              |      |         | 59.6 ± 9.4  | 1:29:1        |                |                                                                                        | Abdominoperineal resection    |
| Guillon et al[32] | 2005 | United  | 69 ± 11   | 44% female   | 3              | Adenocarcinoma of left colon and rectum                                                | Anterior resection and        |
| OTME              |      |         | 69 ± 12   | 46% female   |                |                                                                                        | Abdominoperineal resection    |
| Jayne et al[30]   | 2007 | United  | 69 ± 11   | 44% female   | 36.5           | Lower and mid rectal adenocarcinoma with neoadjuvant chemoradiotherapy                 | Anterior resection and        |
| OTME              |      |         | 69 ± 12   | 46% female   |                |                                                                                        | Abdominoperineal resection    |
| Kang et al[34]    | 2010 | South   | 57.8 ± 11.1 | 110:60       | 3              | Upper rectal adenocarcinoma                                                             | Anterior resection and        |
| OTME              |      |         | 59.1 ± 9.9 | 110:60       |                |                                                                                        | Abdominoperineal resection    |
| Lujan et al[35]   | 2009 | Spain   | 67.8 ± 12.9 | 62:39        | 32.8           | Mid or low rectal adenocarcinoma cT3N0-2 stage                                         | Preoperative chemoradiotherapy|
| OTME              |      |         | 66 ± 9.9  | 64:39        |                |                                                                                        | Lower rectal cancer within 5 cm of the anal verge                                   | Abdominoperineal resection    |
| Ng et al[33]      | 2008 | Hong    | 63.7 ± 11.8 | 31:20        | 90.1           |                                                                                       |                                |
| OTME              |      |         | 63.5 ± 12.6 | 30:18        | 87.2           |                                                                                        |                                |
| Ng et al[37]      | 2009 | Hong    | 66.5 ± 11.9 | 37:39        | 112.5          |                                                                                       |                                |
| OTME              |      |         | 65.7 ± 12   | 48:29        | 108.8          |                                                                                        |                                |
| Ng et al[36]      | 2013 | Hong    | 60.2 ± 11.3 | 24:16        | 84.6           | Rectal adenocarcinoma located between 5 and 12 cm from the anal verge. None of the included patient had neoadjuvant treatment | Sphincter sparing total       |
| OTME              |      |         | 62.1 ± 12.6 | 22:18        | 92.7           |                                                                                        | mesorectal excision           |
| Zhou et al[34]    | 2004 | China   | 26-85(44)  | 43:46        | 1-16           | Low rectal adenocarcinoma                                                             | Anterior resection            |
| OTME              |      |         | 30-81(45)  | 46:36        |                |                                                                                        |                                |

LTME: Laparoscopic total mesorectal excision; OTME: Open total mesorectal excision; M: Male; F: Female.

Differential resection margins was similar following both approaches.

**Number of harvested lymph nodes**

There was significant heterogeneity \( \chi^2 = 48.61, \gamma = 8, (P > 0.00001); I^2 = 84\% \) among included studies. In the random effects model (SMD, -0.14; 95%CI: -0.40-0.12; \( z = 1.08; P < 0.28; \) Figure 3C), the number of harvested lymph nodes following both procedures was statistically similar.

**Recurrence**

There was no heterogeneity \( \chi^2 = 0.00; I^2 = 4.57, \gamma = 7, (P = 0.71); F = 0\% \) among included studies. In the random effects model (OR = 0.82; 95%CI: 0.59-1.15; \( z = 1.16; P = 0.24; \) Figure 3D), the risk of rectal cancer recurrence was similar between both types of excisions.

**Duration of hospital stay**

There was significant heterogeneity \( \chi^2 = 82.18, \gamma = 9, (P < 0.00001); I^2 = 89\% \) among included studies. In the random effects model (SMD, -1.59; 95%CI: -0.86--0.25; \( z = 4.22; P < 0.00001; \) Figure 3E), the length of hospital stay was shorter following LTME compared to OTME.

**Short term and long term operative complications**

There was significant heterogeneity \( \chi^2 = 28.55, \gamma = 9, (P < 0.00008); I^2 = 68\% \) among included studies. In the random effects model (OR = 0.69; 95%CI: 0.43, 1.08; \( z = 1.62; P = 0.11; \) Figure 3F), the incidence of complications was similar following both approaches of rectal cancer resection.

**Overall mortality**

There was no heterogeneity \( \chi^2 = 0.00, \gamma = 0.45, (P = 3; \) \( F = 0\% \) among included studies. In the random effects model (OR = 0.70; 95%CI: 0.41-1.18; \( z = 1.33; P = 0.18; \) Figure 3G), the incidence of overall mortality was similar following LTME and OTME.

**Anastomosis leak**

There was no heterogeneity \( \chi^2 = 6.18, \gamma = 7, (P = 0.52; F = 0\% \) among included studies. In the
random effects model (OR = 0.92; 95%CI: 0.56-1.50; z = 0.33; P = 0.74; Figure 3H), the risk of colorectal anastomotic dehiscence was similar following both approaches.

**Surgical site infection**

There was significant no heterogeneity (I$^2$ = 0.07, $\chi^2$ = 10.61, $\gamma = 9, (P = 0.30); F = 15% among included studies. In the random effects model (OR = 0.66; 95%CI: 0.44-1.00; z = 1.94; P < 0.05; Figure 3I), the risk of surgical site infection was higher following OTME compared to LTME.

**DISCUSSION**

Based upon the findings of this largest ever systematic review of eleven randomized, controlled trial on 2143
Sajid MS et al. Laparoscopic TME for rectal cancer

| Outcomes                                      | Illustrative comparative risks* (95%CI) | Relative effect (95%CI) | No of participants (students) | Quality of the evidence (GRADE) | Comments |
|-----------------------------------------------|----------------------------------------|-------------------------|-------------------------------|---------------------------------|----------|
| **Incidence of incomplete TME**              | Control: 85 per 1000 (38 to 78)        | OR = 0.62 (0.43 to 0.91) | 1762                          | Moderate                        |          |
| OR follow-up: 3-12 mo                        | Case: 54 per 1000 (38 to 78)           |                         |                               |                                 |          |
| settings:                                    | Moderate: 0 per 1000 (0 to 0)          |                         |                               |                                 |          |
| **Incidence of CRM positivity**              | Control: 54 per 1000 (36 to 81)        | OR = 0.98 (0.63 to 1.51) | 1563                          | Moderate                        |          |
| OR follow-up: 3-112 mo                       | Case: 34 per 1000 (22 to 52)           |                         |                               |                                 |          |
| settings:                                    | Moderate: 35 per 1000 (22 to 52)       |                         |                               |                                 |          |
| **Number of harvested lymph nodes**          | The mean number of harvested lymph     | OR = 0.82 (0.59 to 1.15) | 1422                          | Moderate                        |          |
| nodes in the intervention groups was         | nodes in the intervention groups was   |                         |                               |                                 |          |
| standardized mean difference                  | 0.14 standard deviations lower (0.4  lower to 0.12 higher) | | | | |
| follow-up: 3-112 mo                          |                                           |                         |                               |                                 |          |
| settings:                                    |                                           |                         |                               |                                 |          |
| **Recurrence**                               | Control: 131 per 1000 (82 to 148)      | OR = 0.82 (0.59 to 1.15) | 1422                          | Moderate                        |          |
| OR follow-up: 3-112 mo                       | Case: 110 per 1000 (82 to 148)          |                         |                               |                                 |          |
| settings:                                    | Moderate: 133 per 1000 (83 to 150)     |                         |                               |                                 |          |
| **Length of stay**                           | The mean length of stay in the         | OR = 0.69 (0.43 to 1.08) | 1762                          | Moderate                        |          |
| intervention groups was                      | intervention groups was                 |                         |                               |                                 |          |
| standardized mean difference                  | 0.35 standard deviation lower           |                         |                               |                                 |          |
| follow-up: 3-112 mo                          | (0.86 to 0.25 lower)                    |                         |                               |                                 |          |
| settings:                                    |                                           |                         |                               |                                 |          |
| **Short and long term complications**        | Control: 430 per 1000 (245 to 449)     | OR = 0.69 (0.43 to 1.08) | 1762                          | Moderate                        |          |
| OR follow-up: 3-112 mo                       | Case: 342 per 1000 (245 to 449)         |                         |                               |                                 |          |
| settings:                                    | Moderate: 503 per 1000 (303 to 522)    |                         |                               |                                 |          |
| **All cause mortality**                      | Control: 41 per 1000 (17 to 48)        | OR = 0.7 (0.41 to 1.18)  | 1762                          | Moderate                        |          |
| OR follow-up: 3-112 mo                       | Case: 29 per 1000 (17 to 48)           |                         |                               |                                 |          |
| settings:                                    | Moderate: 430 per 1000 (0 to 0)        |                         |                               |                                 |          |
| **Anastomosis leak rate**                    | Control: 46 per 1000 (26 to 67)        | OR = 0.92 (0.56 to 1.5)  | 1732                          | Moderate                        |          |
| OR follow-up: 3-112 mo                       | Case: 42 per 1000 (26 to 67)           |                         |                               |                                 |          |
| settings:                                    | Moderate: 34 per 1000 (19 to 50)       |                         |                               |                                 |          |
| **Surgical site infection**                  | Control: 99 per 1000 (46 to 99)        | OR = 0.66 (0.44 to 1)   | 1762                          | Moderate                        |          |
| OR follow-up: 3-112 mo                       | Case: 68 per 1000 (46 to 99)           |                         |                               |                                 |          |
| settings:                                    | Moderate: 117 per 1000 (55 to 117)     |                         |                               |                                 |          |

*The basis for the assumed risk (e.g., the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95%CI) GRADE Working Group grades of evidence.

High quality: Further research is very unlikely to change our confidence in the estimate of effect.

Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low quality: We are very uncertain about the estimate.

No explanation was provided.

Figure 2 Strength and summary of the evidence analysed on GradePro®.
Table 3  Quality variables reported in the included trials

| Ref.        | Randomization                      | Power calculations | ITT | Blinding                        | Concealment                                        |
|-------------|------------------------------------|--------------------|-----|---------------------------------|----------------------------------------------------|
| Araujo et al[42] | Not reported                        | Not reported       | Not reported | Not reported | Not reported |
| Baraga et al[40] | Computer generated                 | Yes                | Yes  | Yes                             | Sealed blinded envelops                             |
| Gong et al[39]   | Not reported                        | Not reported       | Not reported | Not reported | Not reported |
| Guillou et al[38] | Random allocation with 2 to 1 ratio | Yes                | Yes  | Not reported | Allocation communicated by telephone               |
| Jayne et al[37]  | Random allocation with 2 to 1 ratio | Yes                | Yes  | Not reported | Allocation communicated by telephone               |
| Kang et al[38]   | Computer generated with block permutation | Yes            | Yes  | Yes                             | Allocation communicated by telephone               |
| Lujan et al[36]  | Computer generated                 | Yes                | Yes  | Yes                             | Sealed blinded envelops                             |
| Ng et al[35]     | Computer generated random sequence  | Yes                | Yes  | Not reported | Concealed by theatre coordinator                   |
| Ng et al[34]     | Computer generated random sequence  | Yes                | Yes  | Not reported | Not reported                                       |
| Zhou et al[32]   | Not reported                        | Not reported       | Not reported | Not reported | Not reported                                       |

ITT: Intention-to-treat.
Sajid MS et al. Laparoscopic TME for rectal cancer

### D

| Study or subgroup | LTME Events | OTME Events | Odds ratio M-H, random, 95%CI |
|------------------|-------------|-------------|-------------------------------|
| Araujo 2003      | 0           | 13          | 0.20 [0.01, 4.57]             |
| Baraga 2007      | 3           | 83          | 0.76 [0.16, 3.50]             |
| Gong 2012        | 0           | 67          | Not estimable                 |
| Guillou 2005     | 72          | 253         | 1.10 [0.68, 1.77]             |
| Lujan 2009       | 5           | 101         | 0.84 [0.25, 2.85]             |
| Ng 2008          | 8           | 51          | 0.50 [0.19, 1.34]             |
| Ng 2009          | 9           | 76          | 0.81 [0.31, 2.07]             |
| Ng 2013          | 7           | 40          | 0.44 [0.15, 1.26]             |
| Zhou 2004        | 2           | 82          | 0.72 [0.12, 4.40]             |

**Total (95%CI):** 766 656 100.0%

Test for overall effect: Z = 1.16 (P = 0.24)

### E

| Study or subgroup | LTME Mean | STD | OTME Mean | SD | Total | Std. Mean Difference IV, random, 95%CI |
|------------------|-----------|-----|-----------|----|-------|--------------------------------------|
| Araujo 2003      | 10.5      | 3.2 | 9.5       | 3.2| 15    | 0.30 [-0.44, 1.05]                   |
| Baraga 2007      | 10.4      | 4.3 | 13.6      | 7  | 9     | -0.45 [-0.76, -0.15]                |
| Gong 2012        | 10.4      | 4.3 | 13.8      | 5.9| 71    | -0.65 [-0.99, -0.31]                |
| Guillou 2005     | 11        | 1.5 | 23.3      | 12.8| 128   | -1.12 [-1.34, -0.89]               |
| Kao 2010         | 8.2       | 1.25| 17.0      | 1   | 170   | -0.88 [-1.10, -0.66]               |
| Lujan 2009       | 8.2       | 7.3 | 9.9       | 6.8| 103   | -0.24 [-0.52, 0.04]                |
| Ng 2008          | 10.8      | 5.5 | 11.5      | 8.25| 48    | -0.10 [-0.49, 0.29]                |
| Ng 2009          | 8.4       | 5   | 7.6       | 10 | 77    | -0.29 [-0.61, 0.03]                |
| Ng 2013          | 10.5      | 4.5 | 40        | 15 | 40    | -0.16 [-0.59, 0.28]                |
| Zhou 2004        | 8.1       | 3.1 | 82        | 13.3| 34    | -1.59 [-1.93, -1.24]               |

**Total (95%CI):** 936 826 100.0%

Test for overall effect: Z = 3.53 (P = 0.0004)

### F

| Study or subgroup | LTME Events | OTME Events | Odds ratio M-H, random, 95%CI |
|------------------|-------------|-------------|-------------------------------|
| Araujo 2003      | 11          | 13          | 2.00 [0.30, 13.26]            |
| Baraga 2007      | 29          | 83          | 0.52 [0.28, 0.98]             |
| Gong 2012        | 4           | 67          | 0.69 [0.19, 2.55]             |
| Guillou 2005     | 150         | 253         | 1.46 [0.95, 2.23]             |
| Kang 2010        | 45          | 170         | 0.86 [0.54, 1.39]             |
| Lujan 2009       | 47          | 101         | 1.17 [0.67, 2.03]             |
| Ng 2008          | 39          | 51          | 0.07 [0.01, 0.56]             |
| Ng 2009          | 35          | 70          | 0.71 [0.38, 1.34]             |
| Ng 2013          | 31          | 40          | 0.03 [0.00, 0.23]             |
| Zhou 2004        | 5           | 82          | 0.46 [0.15, 1.39]             |

**Total (95%CI):** 936 826 100.0%

Test for overall effect: Z = 1.62 (P = 0.11)

### G

| Study or subgroup | LTME Events | OTME Events | Odds ratio M-H, random, 95%CI |
|------------------|-------------|-------------|-------------------------------|
| Araujo 2003      | 0           | 13          | Not estimable                 |
| Baraga 2007      | 1           | 83          | 1.02 [0.06, 16.65]            |
| Gong 2012        | 0           | 67          | Not estimable                 |
| Guillou 2005     | 21          | 253         | 0.80 [0.39, 1.66]             |
| Kang 2010        | 0           | 170         | Not estimable                 |
| Lujan 2009       | 2           | 101         | 0.67 [0.11, 4.12]             |
| Ng 2008          | 12          | 51          | 0.56 [0.23, 1.35]             |
| Ng 2009          | 0           | 76          | Not estimable                 |
| Ng 2013          | 0           | 40          | Not estimable                 |
| Zhou 2004        | 0           | 82          | Not estimable                 |

**Total (95%CI):** 936 826 100.0%

Test for overall effect: Z = 1.33 (P = 0.18)
patients of rectal cancer, there is a higher risk of surgical site infection, higher risk of incomplete total mesorectal resection and prolonged length of hospital stay following OTME compared to LTME. The oncological outcomes like the number of harvested lymph nodes, incidence of tumour recurrence and risk of positive resection margins were statistically similar in both groups. In addition, the clinical outcomes such as operative complications, anastomotic leak and all-cause mortality were comparable between both approaches of the mesorectal excision. LTME appears to have clinically and oncologically measurable advantages over OTME in patients with primary resectable rectal cancer in both short term and long term follow ups.

The findings of this article are consistent with previously published Cochrane review and a meta-analysis\[3,4\]. Majority of the studies in the Cochrane review\[14-16\] were non-randomized, trials and therefore the conclusion was considered weaker and biased. Similarly a recently published meta-analysis\[13\] failed to demonstrate the oncological safety and advantages of LTME over OTME.

This review article presents a comprehensive assessment on the oncological safety of the LTME in addition to the proven clinical advantages of laparoscopy in the curative resections of rectal cancer. Proven clinical advantages of LTME have also been reported in many published studies\[32-34\] which include the lesser blood loss, shorter length of hospital stay and lower postoperative pain score. In addition, the oncological adequacy of LTME has been confirmed in many recent publications\[35-37\].

Authors are fully aware of the fact that there are several limitations to this study. There is significant heterogeneity among included studies. Causes of heterogeneity are both clinical as well as methodological in terms of trial recruitment process. Included studies recruited patients with different stages of the rectal cancer and therefore one would expect their oncological outcome different. Combined analysis of studies on rectal cancer patients with and without neoadjuvant treatment can potentially influence the oncological outcomes which would result in biased conclusions. Variable grade and stage of the disease in recruited patients can also manipulate overall
survival and risk of recurrence. Preoperative nodal disease staging by MRI scan is a standard approach and all included studies did report the use of this imaging prior to surgery. Preoperative diagnostic and staging modalities across the included trials were significantly heterogeneous and therefore can potentially be a strong source of study sample contamination leading to biased outcomes. Colorectal follow up protocol among various centres conducting these trials was significantly diverse and inconsistent. Future trials should be directed towards the involvement of major colorectal units recruiting patients of similar stage and grade of the disease with different arms evaluating outcomes with and without neoadjuvant chemo-radiotherapy. In addition, an agreed preoperative staging as well follow up protocol will also help to curtail the clinical and methodological flaws reported in previous trials.

**COMMENTS**

**Background**

Total mesorectal excision (TME) has been the gold standard treatment for the management of rectal cancer. Laparoscopic approach for TME has been reported with several advantages such as quicker recovery, reduced postoperative pain and shorter hospital stay. But the limitations compared to open approach include higher cost, longer learning curve and longer operating time.

**Research frontiers**

Due to clinically measureable advantages, the laparoscopic approach may be a preferred way forward as long as oncological safety of both approaches is at least similar. Several non-randomized and randomized studies have reported the inconsistent oncological findings following laparoscopic TME and precise guidelines are still scarce. Since the introduction of new generation of laparoscopic instruments and stapling devices, the recently published studies have reported encouraging results in favor of laparoscopic TME.

**Innovations and breakthroughs**

This article highlights the role of laparoscopic approach for TME in current situations. This article reports the oncological safety of laparoscopic TME in terms of clear circumferential resection margins, number of harvested lymph nodes, recurrence and mortality following both open and laparoscopic TME. This article compared to other peer review publications on the same subject provides the latest and strongest evidence and may assist the colorectal surgeons in decision making.

**Peer review**

It is an important topic, clear presentation, good readability, appropriate methods, precise results, interesting discussion, coherent tables, unambiguous conclusion. This is a very good paper.

**REFERENCES**

1. Morris EJ, Whitehouse LE, Farrell T, Nickerson C, Thomas JD, Quirke P, Rutter MD, Roess C, Finan PJ, Wilkinson JR, Patrick J. A retrospective observational study examining the characteristics and outcomes of tumours diagnosed within and without of the English NHS Bowel Cancer Screening Programme. Br J Cancer 2012; 107: 757-764 [PMID: 22850549 DOI: 10.1038/bjc.2012-03217]

2. Logan RF, Patrick J, Nickerson C, Coleman L, Rutter MD, von Wagner C. Outcomes of the Bowel Cancer Screening Programme (BCSP) in England after the first 1 million tests. Gut 2012; 61: 1439-1446 [PMID: 22156981 DOI: 10.1136/ gutjnl-2011-300843]

3. Vaughan-Shaw PG, Cheung T, Knight JS, Nichols PH, Filkington SA, Mirrmezzi AH. A prospective case-control study of extralevator abdominopelvic excision (ELAPE) of the rectum versus conventional laparoscopic and open abdominopeneral excision: comparative analysis of short-term outcomes and quality of life. Tech Coloproctol 2012; 16: 355-362 [PMID: 22777690 DOI: 10.1007/s10151-012-0851-4]

4. Stelzer S, Hellmich G, Schubert C, Puffer E, Haroske G, Witzigmann H. Short-term outcome of extra-levator abdominopelvic excision for rectal cancer. Int J Colorectal Dis 2011; 26: 919-925 [PMID: 21350936 DOI: 10.1007/s00384-011-1157-0]

5. Mauvais F, Sabbagh C, Brehant O, Viart L, Benhaim T, Fuks D, Sinna R, Regimbeau JM. The current abdominopelvic resection: oncological problems and surgical modifications for low rectal cancer. J Visc Surg 2011; 148: e85-e90 [PMID: 21481666 DOI: 10.1016/j.viscsurg.2011.03.001]

6. Reshef A, Lavery I, Kiran RP. Factors associated with oncoplastic outcomes after abdominopelvic resection compared with restorative resection for low rectal cancer: patient- and tumor-related or technical factors only? Dis Colon Rectum 2012; 55: 51-58 [PMID: 22156687 DOI: 10.1097/DCR.0b013e3182531c11]

7. Llaguna OH, Calvo BF, Stitzenberg KB, Deal AM, Burke CT, Dixon RG, Stavas JM, Meyers MO. Utilization of interventional radiology in the postoperative management of patients after surgery for locally advanced and recurrent rectal cancer. Am Surg 2011; 77: 1086-1090 [PMID: 21944529]

8. Araújo SE, Seid VE, Bertontoni A, Campos FG, Sousa A, Nahas SC, Ceccionello I. Laparoscopic total mesorectal excision for rectal cancer after neoadjuvant treatment: targeting sphincter-preserving surgery. Hepatogastroenterology 2011; 58: 1545-1554 [PMID: 21940316 DOI: 10.5754/hege.11114]

9. Goldberg S, Klas JV. Total mesorectal excision in the treatment of rectal cancer: a view from the USA. Semin Surg Oncol 1998; 15: 87-90 [PMID: 9730414]

10. Heald RJ. Total mesorectal excision is optimal surgery for rectal cancer: a Scandinavian consensus. Br J Surg 1995; 82: 1297-1299 [PMID: 7489148 DOI: 10.1002/bjs.1800821002]

11. Heald RJ. Total mesorectal excision. Acta Chir Iowa 1998; 85: 37-38 [PMID: 10951785]

12. Hong D, Tabet J, Anvari M. Laparoscopic vs. open resection for colorectal adenocarcinoma. Dis Colon Rectum 2001; 44: 10-8; discussion 18-9 [PMID: 11805558 DOI: 10.1007/BF02234812]

13. Santoro E, Carlini M, Carboni F, Feroce A. Colorectal cancer: laparoscopic versus traditional open surgery. A clinical trial. Hepatogastroenterology 1999; 46: 900-904 [PMID: 10370635]

14. Braga M, Vignali A, Gianotti L, Zuliani W, Radaelli G, Gruarin P, Dellabona P, Di Carlo V. Laparoscopic versus open colorectal surgery: a randomized trial on short-term outcome. Ann Surg 2002; 236: 759-66; discussion 767 [PMID: 12454514 DOI: 10.1097/00000658-200212000-00008]

15. Pikarsky AJ, Rosenthal R, Weiss EG, Wexner SD. Laparoscopic total mesorectal excision. Surg Endosc 2002; 16: 538-562 [PMID: 11972187 DOI: 10.1007/s00464-001-8250-3]

16. Mavrantonis C, Wexner SD, Nogueras JJ, Weiss EG, Potenti F, Pikarsky AJ. Current attitudes in laparoscopic colorectal surgery. Surg Endosc 2002; 16: 1152-1157 [PMID: 12015620 DOI: 10.1007/s00464-008-0072]

17. Breukink SO, Pieper JP, Grond AJ, Hoff C, Wiggers T, Meijerink WJ. Laparoscopic versus open total mesorectal excision: a case-control study. Int J Colorectal Dis 2005; 20: 428-433 [PMID: 15807820 DOI: 10.1007/s00464-004-9066-8]

18. Köcklering F, Reymond MA, Schneider C, Wittekind C, Scheidbach H, Konradt J, Köhler L, Barleiner E, Kuthe A, Bruch HP, Hohenberger W. Prospective multicenter study of the quality of oncologic resections in patients undergoing laparoscopic colorectal surgery for cancer. The Laparoscopic Colorectal Surgery Study Group. Dis Colon Rectum 1998; 41: 963-970 [PMID: 9715150 DOI: 10.1053/dc.1998.12881]

19. Rullier E, Sa Cunha A, Couderc P, Rullier A, Gontier R, Saric J. Laparoscopic intersphincteric resection with coloplasty.
and colonoal anastomosis for mid and low rectal cancer. *Br J Surg* 2003; 90: 445-451 [PMID: 12677346 DOI: 10.1002/ bjs.4052]

20 **Weeks JC**, Nelson H, Gelber S, Sargent D, Schroeder G. Short-term quality-of-life outcomes following laparoscopic-assisted colectomy vs open colectomy for colon cancer: a randomized trial. *JAMA* 2002; 287: 321-328 [PMID: 11790211 DOI: 10.1001/jama.287.3.321]

21 **Cheung HY**, Ng KH, Leung AL, Chung CC, Yau KK, Li MK. Laparoscopic sphincter-preserving total mesorectal excision: 10-year report. *Colorectal Dis* 2011; 13: 627-631 [DOI: 10.1111/j.1463-1318.2010.02235.x]

22 **Higgins JPT**, Green S, editors. *Cochrane Handbook for Systematic Reviews of Interventions*. Available from: URL: http://www.cochrane-handbook.org [Accessed on 12th January 2014].

23 Review Manager (RevMan)[Computer program]. Version 5.0. The Nordic Cochrane Centre, The Cochrane Collaboration: Copenhagen, 2008. Available from: URL: http://rwww.cochrane.org/revman/download

24 **DeCesnimon B**, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986; 7: 177-188 [PMID: 3802833 DOI: 10.1016/0197-2456(86)90046-2]

25 **Demets DL**. Methods for combining randomized clinical trials: strengths and limitations. *Stat Med* 1987; 6: 341-350 [PMID: 3616287 DOI: 10.1002/sim.4780060325]

26 **Higgins JP**, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med* 2002; 21: 1539-1558 [DOI: 12111919 DOI: 10.1002/sim.4780060325]

27 **Egger M**, Smith GD, Altman DG. Systematic reviews in healthcare. London: BMJ Publication Group, 2006

28 **Deeks JJ**, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Smith GD, Altman DG, editors. Systemic reviews in healthcare: meta-analysis in context. 2nd ed. London: BMJ Publication Group, 2001: 285-312

29 **Jadad AR**, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? *Control Clin Trials* 1996; 17: 1-12 [PMID: 8721797 DOI: 10.1016/0197-2456(95)00134-4]

30 **Chalmers TC**, Smith H, Blackburn B, Silverman B, Schroeder B, Reitman D, Ambroz A. A method for assessing the quality of a randomized control trial. *Control Clin Trials* 1981; 2: 31-49 [PMID: 7261638 DOI: 10.1016/0197-2456(81)90036-8]

31 **Cochrane IMS**. Available from: URL: http://ims.cochrane.org/revman/otherresources/gradepro/download. [Accessed on Jan 12, 2014]

32 **Araujo SE**, da Silva e Sousa AH, de Campos FG, Habr-Gama A, Dumanco RB, Caravatto PP, Nahas SC, da Silva J, Kiss DR, Gama-Rodrigues JJ. Conventional approach x laparoscopic abdominoperineal resection for rectal cancer treatment after neoadjuvant chemoradiation: results of a prospective randomized trial. *Rev Hosp Clin Fac Med Sao Paulo* 2003; 58: 133-140 [PMID: 12894309 DOI: 10.1590/ S0041-8781200300030002]

33 **Braga M**, Frasson M, Vignali A, Zuliani W, Capretti G, Di Carlo V. Laparoscopic resection in rectal cancer patients: outcome and cost-benefit analysis. *Dis Colon Rectum* 2007; 50: 464-471 [PMID: 17195085 DOI: 10.1007/s10350-006-0798-5]

34 **Gong J**, Shi DB, Li XX, Cai SJ, Guan QZ, Xu Y. Short-term outcomes of laparoscopic total mesorectal excision compared to open surgery. *World J Gastroenterol* 2012; 18: 7308-7313 [PMID: 23326138 DOI: 10.3748/wjg.v18.i48.7308]

35 **Guillou P**, Quirke P, Thorpe H, Walker J, Jayne DG, Smith AM, Heath RM, Brown JM. Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial. *Lancet* 2005; 365: 1718-1726 [PMID: 15984096 DOI: 10.1016/S0140-6736(05)66545-2]

36 **Jayne DG**, Guillou P, Thorpe H, Quirke P, Copeland J, Smith AM, Heath RM, Brown JM. Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC Trial Group. *J Clin Oncol* 2007; 25: 3061-3068 [PMID: 17634484 DOI: 10.1200/JCO.2006.09.7758]

37 **Kang SB**, Park W, Jeong SY, Nam BH, Choi HS, Kim DW, Lim SB, Lee TG, Kim DY, Kim JS, Chang HJ, Lee HS, Kim SY, Jung KH, Hong YS, Kim JH, Sohn DK, Kim DH, Oh JH. Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiation therapy (COREAN trial): short-term outcomes of an open-label randomised controlled trial. *Lancet Oncol* 2010; 11: 637-645 [PMID: 20610322]

38 **Lujan J**, Valero G, Hernandez Q, Sanchez A, Frutos MD, Parrilla P. Randomized clinical trial comparing laparoscopic and open surgery in patients with rectal cancer. *Br J Surg* 2009; 96: 982-989 [PMID: 19644973 DOI: 10.1002/bjs.6662]

39 **Ng SS**, Leung KL, Lee JF, Yuu RY, Li JC, Teoh AY, Leung WW. Laparoscopic-assisted versus open abdominoperineal resection for low rectal cancer: a prospective randomised trial. *Ann Surg Oncol* 2008; 15: 2418-2425 [PMID: 18392659 DOI: 10.1245/s10434-008-9895-0]

40 **Ng SS**, Leung KL, Lee JF, Yuu RY, Li JC, Hon SS. Long-term morbidity and oncologic outcomes of laparoscopic-assisted anterior resection for upper rectal cancer: ten-year results of a prospective, randomized trial. *Dis Colon Rectum* 2009; 52: 558-566 [PMID: 19404055 DOI: 10.1007/ DCR.0b013e31819ec20c]

41 **Ng SS**, Leung KL, Lee JF, Yuu RY, Li JC, Hon SS, Mak TW, Ngo DK, Leung WW, Leung KL. Laparoscopic-assisted versus open total mesorectal excision with anal sphincter preservation for mid and low rectal cancer: a prospective, randomized trial. *Surg Endosc* 2014; 28: 297-306 [PMID: 24013470 DOI: 10.1007/ s00464-013-3187-x]

42 **Zhou ZG**, Hu M, Li Y, Lei WZ, Yu YY, Cheng Z, Li L, Shu Y, Wang TC. Laparoscopic versus open total mesorectal excision with anal sphincter preservation for low rectal cancer. *Surg Endosc* 2004; 18: 1211-1215 [PMID: 15457380]

43 **Rondelli F**, Trastulli S, Avenia N, Schiacci G, Cirocchi R, Guilla M, Mariani E, Bistoni G, Noya G. Is laparoscopic right colectomy more effective as open resection? A meta-analysis of randomized and nonrandomized studies. *Colorectal Dis* 2012; 14: e447-e469 [PMID: 22540533 DOI: 10.1111/ j.1463-1318.2012.03054.x]

44 **Schwenk W**, Haase O, Neudecker J, Müller JM. Short term benefits for laparoscopic colorectal resection. *Cochrane Database Syst Rev* 2005; (3): CD003145 [PMID: 16034888]

P-Reviewers: Agarwal BB, Par GD, Perathoner A
S-Editor: Wen LI
L-Editor: A
E-Editor: Zhang DN
